SIA
LXRX icon

Schechter Investment Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History

Schechter Investment Advisors’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-14,217
Closed -$56K – 952
2021
Q4 		$56K Buy
+14,217
New +$69.1K 0.01% 857

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Schechter Investment Advisors's LXRX Position: Q1 2022 in Review

Schechter Investment Advisors sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2022, closing a stake of 14,217 shares — an estimated $56K sold.

Schechter Investment Advisors first reported a position in LXRX in Q4 2021 and held it in 1 quarter. The position peaked at $56K in Q4 2021. 101 funds tracked by Wall St. Rank hold LXRX as of Q1 2022.

  • Schechter Investment Advisors reported no remaining Lexicon Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Schechter Investment Advisors sold 14,217 Lexicon Pharmaceuticals shares in Q1 2022, an estimated $56K.
  • Schechter Investment Advisors first reported a position in Lexicon Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Schechter Investment Advisors's Lexicon Pharmaceuticals position peaked at $56K in Q4 2021.
  • 101 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2022.

Based on Schechter Investment Advisors's 13F filing for Q1 2022, filed 18 Nov 2022.